While the advent of anti-amyloid monoclonal antibodies marked a major therapeutic milestone, their use in APOE4 carriers is limited by the elevated risk of amyloid-related imaging abnormalities (ARIA), including cerebral hemorrhage and edema38,39. This evidence concerns the gene APOE and amyloidosis.